ATAI
has the potential for like rapid onset efficacy with improved safety and tolerability summary | ATAI
Company
Deck Type
Sector
Industry
Deck date
May 2023
Slide
12 of 14
Similar slides by ATAI
See diffirences between slides (animation)
Investor Presentation
April 2023
summary has the potential for like rapid onset efficacy with improved safety and tolerability | ATAI
Investor Presentation
March 2023
summary has the potential for like rapid onset efficacy with improved safety and tolerability | ATAI
Investor Presentation
February 2023
summary has the potential for like rapid onset efficacy with improved safety and tolerability | ATAI
Investor Presentation
January 2023
summary has the potential for like rapid onset efficacy with improved safety and tolerability | ATAI
Related slides by other companies
Bionomics
Investor Presentation
April 2022
rapid onset of action is well positioned for social anxiety disorder prescribed off label have significant side effects of sedation cognitive impairment and potential for addiction growing unmet need based on improving awareness and evolving regulatory dynamics precedent on simplified public speaking challenge for acute anxiety reduction placebo be | Bionomics
Kymera
Investor Presentation
August 2023
phase trial design and summary | Kymera
Kymera
Investor Presentation
June 2023
phase trial design and summary | Kymera
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Presentation
April 2023
Investor Presentation
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io